Page 340 - Read Online

Mizejewski. J Cancer Metastasis Treat 2018;4:27 I http://dx.doi.org/10.20517/2394-4722.2018.20 Page 7 of 7

different physical properties in circulating tumor cells from metastatic breast cancer. Oncotarget 2016;7:24677-87.
13. Jordan NV, Bardia A, Wittner BS, Benes C, Ligorio M, Zheng Y, Yu M, Sundaresan TK, Licausi JA, Desai R, O’Keefe RM, Ebright RY,
Boukhali M, Sil S, Onozato ML, Iafrate AJ, Kapur R, Sgroi D, Ting DT, Toner M, Ramaswamy S, Haas W, Maheswaran S, Haber DA.
HER2 expression identifies dynamic functional states within circulating breast cancer cells. Nature 2016;537:102-6.
14. Valiente M, Obenauf AC, Jin X, Chen Q, Zhang XH, Lee DJ, Chaft JE, Kris MG, Huse JT, Brogi E, Massague J. Serpins promote cancer
cell survival and vascular co-option in brain metastasis. Cell 2014;156:1002-16.
15. Alix-Panabieres C, Pantel K. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov
2016;6:479-91.
16. Ingham KC, Brew SA, Erickson HP. Localization of a cryptic binding site for tenascin on fibronectin. J Biol Chem 2004;279:28132-5.
17. Cao Y, Ji RW, Davidson D, Schaller J, Marti D, Sohndel S, McCance SG, O’Reilly MS, Llinas M, Folkman J. Kringle domains of human
angiostatin. Characterization of the anti-proliferative activity on endothelial cells. J Biol Chem 1996;271:29461-7.
18. Folkman J. Antiangiogenesis in cancer therapy--endostatin and its mechanisms of action. Exp Cell Res 2006;312:594-607.
19. Pike SE, Yao L, Jones KD, Cherney B, Appella E, Sakaguchi K, Nakhasi H, Teruya-Feldstein J, Wirth P, Gupta G, Tosato G. Vasostatin, a
calreticulin fragment, inhibits angiogenesis and suppresses tumor growth. J Exp Med 1998;188:2349-56.
20. Kamphaus GD, Colorado PC, Panka DJ, Hopfer H, Ramchandran R, Torre A, Maeshima Y, Mier JW, Sukhatme VP, Kalluri R. Canstatin, a
novel matrix-derived inhibitor of angiogenesis and tumor growth. J Biol Chem 2000;275:1209-15.
21. Mizejewski GJ, MacColl R. Alpha-fetoprotein growth inhibitory peptides: potential leads for cancer therapeutics. Mol Cancer Ther
2003;2:1243-55.
22. Uversky VN, Kirkitadze MD, Narizhneva NV, Potekhin SA, Tomashevski A. Structural properties of alpha-fetoprotein from human cord
serum: the protein molecule at low pH possesses all the properties of the molten globule. FEBS Lett 1995;364:165-7.
23. Mizejewski GJ, Dias JA, Hauer CR, Henrikson KP, Gierthy J. Alpha-fetoprotein derived synthetic peptides: assay of an estrogen-modifying
regulatory segment. Mol Cell Endocrinol 1996;118:15-23.
24. Mizejewski G, Smith G, Butterstein G. Review and proposed action of alpha-fetoprotein growth inhibitory peptides as estrogen and
cytoskeletal-associated factors. Cell Biol Int 2004;28:913-33.
25. Mizejewski GJ, Butterstein G. Survey of functional activities of alpha-fetoprotein derived growth inhibitory peptides: review and prospects.
Curr Protein Pept Sci 2006;7:73-100.
26. Jin J, Niu X, Zou L, Li L, Li S, Han J, Zhang P, Song J, Xiao F. AFP mRNA level in enriched circulating tumor cells from hepatocellular
carcinoma patient blood samples is a pivotal predictive marker for metastasis. Cancer Lett 2016;378:33-7.
27. Mizejewski GJ. Third domain ligand binding fragment of alpha-fetoprotein: detection of metastasis-associated molecular targets. Cancer
Therapy Oncol Int J 2017;6:1-15.
28. Valiente M, Obenauf AC, Jin X, Chen Q, Zhang XH, Lee DJ, Chaft JE, Kris MG, Huse JT, Brogi E, Massague J. Serpins promote cancer
cell survival and vascular co-option in brain metastasis. Cell 2014;156:1002-16.
29. Mizejewski GJ. Mechanism of cancer growth suppression of alpha-fetoprotein derived growth inhibitory peptides (GIP): comparison of
GIP-34 versus GIP-8 (AFPep). Updates and prospects. Cancers (Basel) 2011;3:2709-33.
30. Atemezem A, Mbemba E, Marfaing R, Vaysse J, Pontet M, Saffar L, Charnaux N, Gattegno L. Human alpha-fetoprotein binds to primary
macrophages. Biochem Biophys Res Commun 2002;296:507-14.
31. Mizejewski GJ. Alpha-fetoprotein as a biomarker for immunodeficiency diseases: relevance to ataxia telangiectasia & related disorders. J
Immunodefic Disor 2014;3:1-12.
32. Mizejewski GJ, Muehlemann M, Dauphinee M. Update of alpha fetoprotein growth-inhibitory peptides as biotherapeutic agents for tumor
growth and metastasis. Chemotherapy 2006;52:83-90.
33. Mizejewski GJ. Role of integrins in cancer: survey of expression patterns. Proc Soc Exp Biol Med 1999;222:124-38.
34. Muehlemann M, Miller KD, Dauphinee M, Mizejewski GJ. Review of growth inhibitory peptide as a biotherapeutic agent for tumor growth,
adhesion, and metastasis. Cancer Metastasis Rev 2005;24:441-67.
35. Mizejewski GJ, Mirowski M, Garnuszek P, Maurin M, Cohen BD, Poiesz BJ, Posypanova GA, Makarov VA, Severin ES, Severin SE.
Targeted delivery of anti-cancer growth inhibitory peptides derived from human alpha-fetoprotein: review of an International Multi-Center
Collaborative Study. J Drug Target 2010;18:575-88.
36. Czokalo M, Tomasiak M. Alpha fetoprotein inhibits aggregation of human platelets. Haematologia (Budap) 1989;22:11-8.
37. Hua SC, Chen Sy, Lu CH, Kao YT, Yu HI, Chen, PT, Lee YR, Chang TC. The effects of growth inhibitory peptide on follicular thyroid
cancer cell growth, migration, and invasion. Tumori 2010;96:448-51.